Mokari Atabak 4

What Happened
Mokari Atabak, Chief Financial Officer of Corcept Therapeutics (CORT), received a grant of 140,000 derivative shares (reported as an award) on February 27, 2026. The award was reported at $0.00 per share (no cash paid at grant) and is a compensatory/derivative award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-02-27; Form 4 filed: 2026-03-03.
• Award: 140,000 derivative shares reported at $0.00 per share (code A — award/grant).
• Vesting/exercise: Footnote states the award will be exercised/vest ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period, subject to continued service.
• Shares owned after transaction: not specified in the filing.
• Remarks: Power of attorney under which form was signed is on file with the SEC. No 10b5-1 plan, tax‑withholding, or cashless sale was disclosed.

Context
This is a compensation grant (derivative award) for the CFO, not a market purchase or sale. Such awards typically vest over time and do not represent immediate cash or stock being sold into the market; they may lead to future dilution if exercised or settled in shares. For retail investors, purchases by insiders can be more directly indicative of personal investment; grants primarily reflect company compensation programs.